Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new cannabinoid-like molecules.

NIH-backed work on the two-year grant is expected to begin on July 1, 2026, and represents the second biosolution in eXoZymes' pipeline after NCT advancing towards partnership and commercialization.

Total non-dilutive funding awarded to eXoZymes is now almost $20 million, validating the scalable nature of the Company's platform

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.